On the afternoon of March 19, the joint prevention and control mechanism of the State Council held a press conference. From March 1 to 18, China reported more than 29000 cases of covid-19 pneumonia infection, affecting 28 provinces, including one province in Jilin Province. Another four provinces reported more than 1000 cases, and 10 provinces reported between 1001000 cases.
Therefore, covid-19 therapeutic drugs have attracted extensive attention. Today, covid-19 oral drug hydroxymethylcoumarin concept stocks rise. On the news, on the 20th, the Fudan Shenzhen third hospital joint team publicly announced that clinical trials have proved that oral hydroxymethylcoumarin is safe and effective in the treatment of covid-19. Favorable to relevant stocks of hydroxymethylcoumarin, such as Shanghai Shyndec Pharmaceutical Co.Ltd(600420) , Hunan Er-Kang Pharmaceutical Co.Ltd(300267) , Xiangxue Pharmaceutical Co.Ltd(300147) , Tianjin Zhongxin Pharmaceutical Group Corporation Limited(600329) , Hybio Pharmaceutical Co.Ltd(300199) , etc. As of the closing, of which, Shanghai Shyndec Pharmaceutical Co.Ltd(600420) 10% limit, Hunan Er-Kang Pharmaceutical Co.Ltd(300267) 20% limit, Xiangxue Pharmaceutical Co.Ltd(300147) , Tianjin Zhongxin Pharmaceutical Group Corporation Limited(600329) , Hybio Pharmaceutical Co.Ltd(300199) , etc. followed the rise.
The study showed that for all patients hospitalized for less than 14 days, the lung injury was significantly improved after oral administration of hydroxymethylcoumarin; For patients hospitalized for 14 to 28 days, the improvement of lung injury in the oral hydroxymethylcoumarin group was significantly higher than that in the control group. For patients hospitalized for 28 ~ 35 days, the improvement rate of pulmonary lesions in patients with oral hydroxymethylcoumarin was 86%, and only 45% in the control group.
In addition, according to the official announcement of China Meheco Group Co.Ltd(600056) today, on March 19, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) the first batch of covid-19 virus treatment drug paxlovid cooperated with Pfizer has been transported to China Meheco Group Co.Ltd(600056) Daxing logistics center. All goods have been transported in a closed-loop management throughout the whole process according to the epidemic prevention requirements related to import and export, and the acceptance and warehousing have been completed. At present, the company has received the order of urgent drug guarantee, and all drugs are being transported to the national anti epidemic front line. Pfizer covid-19 oral drug related stocks rose sharply today. As of the close, China Meheco Group Co.Ltd(600056) limit, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Apeloa Pharmaceutical Co.Ltd(000739) limit, Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) rose 7% and Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) rose more than 6%.
hydroxymethylcoumarin is safe and effective in the treatment of covid-19
On the 20th, the 21st Century Business Herald reporter learned from Shenzhen Third People’s hospital that after two years of painstaking research, Professor Yu Wenqiang, a researcher at the Biomedical Research Institute of Fudan University and Shanghai public health clinical center, together with Professor Lu Hongzhou, President of Shenzhen Third People’s Hospital and the solo director of the radiology department of Shanghai public health clinical center, It was found that the increase of hyaluronic acid in patients with covid-19 was related to the progression of covid-19, and an oral drug hydroxymethylcoumarin, which blocked the progression of covid-19 by inhibiting the synthesis of hyaluronic acid, was found. The efficacy and safety of the oral drug were further verified in clinical trials.
Professor Yu Wenqiang pointed out that based on the previous research on the pathogenic mechanism of covid-19 virus, it was further found that the level of hyaluronic acid was correlated with the progress of covid-19 disease. Therefore, the team hoped to find a drug that could inhibit the synthesis of hyaluronic acid and block the progress of covid-19. After careful search, it finally found a drug – hydroxymethylcoumarin. Hydroxymethylcoumarin is not new, but a Chinese drug used to treat gallstones. It has low pharmacological toxicity, can be taken orally and has high safety.
In order to further evaluate whether hydroxymethylcoumarin can effectively alleviate the clinical symptoms of covid-19 patients, the research team recruited 144 covid-19 patients in Shanghai public health clinical center, of which 94 patients took hydroxymethylcoumarin orally and the other 50 patients took the conventional covid-19 treatment strategy.
The study showed that for all patients hospitalized for less than 14 days, the lung injury was significantly improved after oral administration of hydroxymethylcoumarin; For patients hospitalized for 14 to 28 days, the improvement of lung injury in the oral hydroxymethylcoumarin group was significantly higher than that in the control group. For patients hospitalized for 28 ~ 35 days, the improvement rate of pulmonary lesions in patients with oral hydroxymethylcoumarin was 86%, and only 45% in the control group.
Overall, 89% of patients taking oral hydroxymethylcoumarin experienced regression of lung lesions, compared with 42% in the control group. Director Shan Fei further said that the CT results also confirmed that the lung lesions of covid-19 patients were significantly improved after oral administration of hydroxymethylcoumarin compared with the control group.
The effect of “new use of old drugs” of hydroxymethylcoumarin is good, which brings new hope to alleviate the current covid-19 epidemic prevention and control situation. Professor Lu Hongzhou said that he was actively contacting Hong Kong and overseas to plan large-scale multicenter clinical trials to further test the effectiveness of the oral drug and provide a powerful weapon for the treatment and normalization prevention and control of covid-19.
related stocks rose sharply
Affected by the news, today, covid-19 oral drug hydroxymethylcoumarin related concept stocks rose. As of the closing, among them, Shanghai Shyndec Pharmaceutical Co.Ltd(600420) rose by more than 10%, Hunan Er-Kang Pharmaceutical Co.Ltd(300267) by 20%, and Xiangxue Pharmaceutical Co.Ltd(300147) , Tianjin Zhongxin Pharmaceutical Group Corporation Limited(600329) , Hybio Pharmaceutical Co.Ltd(300199) , etc. followed.
Today, Shanghai Shyndec Pharmaceutical Co.Ltd(600420) touched the daily limit, and the stock rose twice in the past year. According to the annual report, the company is mainly engaged in the R & D, production and sales of pharmaceutical products. According to the industry classification guidelines of listed companies issued by the CSRC, the industry is pharmaceutical manufacturing (C27). The company is a high-tech enterprise. Its products cover the treatment fields of anti infection, cardio cerebrovascular, anti-tumor, narcotic spirit, metabolism and endocrine and the field of general health. It has more than 30 dosage forms, including chemical intermediates and APIs (including narcotic spirit controlled products), biochemical APIs, microbial fermentation products and tablets, capsules, injections, granules, suspensions, suppositories and ointments.
Recently, Shanghai Shyndec Pharmaceutical Co.Ltd(600420) also pointed out on the investor platform that the company’s main business is chemical pharmaceutical industry, and the proportion of traditional Chinese medicine products is very small. In the future, the company will adhere to the strategic positioning of “one body and two wings” and create a strategic pattern with “chemical pharmacy as the main body and biopharmaceutical and great health as the two wings”.
According to public information, Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd. produces hydroxymethylcoumarin.
It is worth noting that Hunan Er-Kang Pharmaceutical Co.Ltd(300267) is trading at “20cm” today Hunan Er-Kang Pharmaceutical Co.Ltd(300267) recently said on the investor relations platform that as a professional manufacturer of pharmaceutical excipients, the company has a rich variety of pharmaceutical excipients, which can be widely used in various dosage forms such as injections, oral preparations, granules, capsules and so on. The company will continue to take the national pharmaceutical excipients engineering technology research center as the technical support. Based on the accumulation of many years of research experience and based on the existing varieties, the company will strengthen the customized development of high-end excipients and promote the application of high-end excipients in conventional pharmaceutical preparations.
For hydroxymethylcoumarin, Hunan Er-Kang Pharmaceutical Co.Ltd(300267) said that the company has the approval of hydroxymethylcoumarin capsule and has not produced the product at present.
It is understood that Hunan Er-Kang Pharmaceutical Co.Ltd(300267) share price soared due to the concept of “NMN ageless drug”. Its wholly-owned subsidiary niacin (vitamin B3) passed the GMP inspection and can be used in NMN production. The functions of NMN include anti-aging, DNA repair, anti alcohol and liver protection, vision protection and hearing protection. It is known as “anti-aging medicine” by the outside world. At present, NMN is divided into health products, and the characteristic of health products industry is that it has the dual attributes of medicine and food.
Today, Hybio Pharmaceutical Co.Ltd(300199) share price rose rapidly in midday trading, with an intraday rise of more than 9.6%. In late trading, it was reported at 21.8 yuan / share, up 3.17%. It is reported that Hybio Pharmaceutical Co.Ltd(300199) today pointed out on the interactive platform that its wholly-owned subsidiary Chengji pharmaceutical has the approval of hydroxymethylcoumarin tablets; In addition, it also said that the company has reached cooperation with the National Research Center and Shenzhen third hospital on the household rapid covid-19 virus antigen detection kit. The cooperation is steadily advancing, and the three parties will jointly explore more cooperation opportunities according to the market situation in the future.
It is noteworthy that Xiangxue Pharmaceutical Co.Ltd(300147) , Sunflower Pharmaceutical Group Co.Ltd(002737) and other companies also pointed out that the company does not produce hydroxymethylcoumarin at present.
